Niagen Bioscience (NASDAQ:NAGE) Rating Lowered to Buy at Wall Street Zen

Wall Street Zen cut shares of Niagen Bioscience (NASDAQ:NAGE - Free Report) from a strong-buy rating to a buy rating in a report published on Saturday.

NAGE has been the topic of a number of other reports. Canaccord Genuity Group upped their price target on shares of Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Roth Capital reaffirmed a "buy" rating and issued a $23.00 target price (up from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th.

Niagen Bioscience Stock Down 1.8%

Shares of NAGE traded down $0.26 during trading hours on Friday, reaching $13.88. The company's stock had a trading volume of 707,549 shares, compared to its average volume of 890,676. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 81.65 and a beta of 2.08. The company has a 50 day moving average of $9.58 and a two-hundred day moving average of $7.22. Niagen Bioscience has a 1-year low of $2.31 and a 1-year high of $14.49.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.